1. Home
  2. BHE vs TRVI Comparison

BHE vs TRVI Comparison

Compare BHE & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benchmark Electronics Inc.

BHE

Benchmark Electronics Inc.

HOLD

Current Price

$81.64

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$18.36

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHE
TRVI
Founded
1979
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.6B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
BHE
TRVI
Price
$81.64
$18.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$55.00
$21.55
AVG Volume (30 Days)
318.5K
1.7M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
0.94%
N/A
EPS Growth
N/A
31.91
EPS
0.91
N/A
Revenue
$2,659,108,000.00
N/A
Revenue This Year
$7.03
N/A
Revenue Next Year
$6.57
N/A
P/E Ratio
$89.84
N/A
Revenue Growth
0.11
N/A
52 Week Low
$35.97
$6.93
52 Week High
$100.41
$20.22

Technical Indicators

Market Signals
Indicator
BHE
TRVI
Relative Strength Index (RSI) 48.62 55.11
Support Level $79.59 $17.46
Resistance Level $87.37 $19.89
Average True Range (ATR) 4.13 0.87
MACD 0.27 -0.07
Stochastic Oscillator 67.90 56.37

Price Performance

Historical Comparison
BHE
TRVI

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: